Ian Mongrain
Overview
Explore the profile of Ian Mongrain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pilon M, Hindi J, St-Jean I, Jutras M, Brouillette M, Mongrain I, et al.
Eur J Clin Pharmacol
. 2024 Dec;
81(2):321-332.
PMID: 39704823
Background: Women are underrepresented in drug development trials and there is no sex-tailored drug regimen for most medications. It has been repeatedly shown that women have more adverse drug reactions...
2.
Meloche M, Pilon M, Provost S, Leclair G, Oussaid E, St-Jean I, et al.
J Pers Med
. 2024 Jun;
14(6).
PMID: 38929870
Cohort studies have identified several genetic determinants that could predict the clinical response to allopurinol. However, they have not been commonly used for genome-wide investigations to identify genetic determinants on...
3.
Gagnon D, Barry H, Barhdadi A, Oussaid E, Mongrain I, Lemieux Perreault L, et al.
Sci Data
. 2023 Dec;
10(1):877.
PMID: 38062080
Hotter climates have important impacts on human health and performance. Yet, the cellular and molecular responses involved in human heat stress and acclimation remain understudied. This dataset includes physiological measurements...
4.
Robert S, Pilon M, Oussaid E, Meloche M, Leclair G, Jutras M, et al.
Pharmacol Res Perspect
. 2023 Sep;
11(5):e01137.
PMID: 37732835
Small studies suggest that amiodarone is a weak inhibitor of cytochrome P450 (CYP) 2D6. Inhibition of CYP2D6 leads to increases in concentrations of drugs metabolized by the enzyme, such as...
5.
Laverdiere J, Meloche M, Provost S, Leclair G, Oussaid E, Jutras M, et al.
Pharmacogenomics
. 2023 Jun;
24(8):441-448.
PMID: 37307170
Few genome-wide association studies (GWASs) have been conducted to identify predictors of drug concentrations. The authors therefore sought to discover the pharmacogenomic markers involved in metoprolol pharmacokinetics. The authors performed...
6.
Hindi J, Pilon M, Meloche M, Leclair G, Oussaid E, St-Jean I, et al.
Clin Transl Sci
. 2023 Mar;
16(5):872-885.
PMID: 36864560
Females present a higher risk of adverse drug reactions. Sex-related differences in drug concentrations may contribute to these observations but they remain understudied given the underrepresentation of females in clinical...
7.
Dube M, Chazara O, Lemacon A, Asselin G, Provost S, Barhdadi A, et al.
ESC Heart Fail
. 2022 Jun;
9(5):2997-3008.
PMID: 35736394
Aims: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme consisted of three parallel, randomized, double-blind clinical trials comparing candesartan with placebo in patients with...
8.
Pilon M, Leclair G, Oussaid E, St-Jean I, Jutras M, Gaulin M, et al.
Clin Transl Sci
. 2022 Jun;
15(8):2024-2034.
PMID: 35689378
ABCG2 is a gene that codes for the human breast cancer resistance protein (BCRP). It is established that rs2231142 G>T, a single nucleotide polymorphism of the ABCG2 gene, is associated...
9.
Meloche M, Leclair G, Jutras M, Oussaid E, Gaulin M, Mongrain I, et al.
Clin Transl Sci
. 2022 Feb;
15(4):1063-1073.
PMID: 35122397
Large, observational genetic studies are commonly used to identify genetic factors associated with diseases and disease-related traits. Such cohorts have not been commonly used to identify genetic predictors of drug...
10.
Dube M, Lemacon A, Barhdadi A, Lemieux Perreault L, Oussaid E, Asselin G, et al.
Sci Rep
. 2021 May;
11(1):10847.
PMID: 34035401
We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial....